Viveve Medical, Inc. (VIVE)

OTCMKTS: VIVE · Delayed Price · USD
0.0002
0.00 (0.00%)
Apr 17, 2024, 9:31 AM EDT - Market open
Market Cap 2.15K
Revenue (ttm) 6.83M
Net Income (ttm) -23.92M
Shares Out 10.72M
EPS (ttm) -2.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 150
Open 0.0002
Previous Close 0.0002
Day's Range 0.0002 - 0.0002
52-Week Range 0.0001 - 0.1107
Beta 0.14
Analysts n/a
Price Target n/a
Earnings Date Aug 22, 2023

About VIVE

Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components. It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Mi... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2005
Employees 47
Stock Exchange OTCMKTS
Ticker Symbol VIVE
Full Company Profile

Financial Performance

In 2021, Viveve Medical's revenue was $6.43 million, an increase of 17.28% compared to the previous year's $5.48 million. Losses were -$22.82 million, 7.46% more than in 2020.

Financial Statements

News

Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence

Study's primary efficacy endpoint was not achieved at 12 months post-treatment Company has implemented a reduction in force Company will seek strategic alternatives and will be delisted from Nasdaq EN...

1 year ago - Accesswire

Viveve Announces Completion of Pivotal US PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits Concluded

Topline results of the 12-month primary efficacy endpoint anticipated in January 2023 Positive results may support a de novo marketing application for a new U.S. indication for treatment of stress uri...

1 year ago - Accesswire

Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence

Patent further strengthens Viveve's novel dual-energy technology intellectual property portfolio as company plans for completion of pivotal PURSUIT clinical trial ENGLEWOOD, CO / ACCESSWIRE / December...

1 year ago - Accesswire

Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Total revenue of $1.7 million in Q3 including sale of 3,100 disposable treatment tips PURSUIT clinical trial completion expected by year-end Conference call to be hosted by Company at 5:00 PM ET today...

1 year ago - Accesswire

Viveve to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10, 2022

ENGLEWOOD, CO / ACCESSWIRE / October 27, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today...

1 year ago - Accesswire

Viveve Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary Incontinence

Patent issuance further strengthens Viveve's intellectual property portfolio for the treatment of female stress urinary incontinence ENGLEWOOD, CO / ACCESSWIRE / October 4, 2022 / Viveve Medical, Inc....

1 year ago - Accesswire

Viveve to Participate in Ladenburg Thalmann Healthcare Conference

ENGLEWOOD, CO / ACCESSWIRE / September 22, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), tod...

1 year ago - Accesswire

Viveve to Participate in Alliance Global Partners Virtual MedTech Conference

ENGLEWOOD, CO / ACCESSWIRE / September 15, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), tod...

1 year ago - Accesswire

Viveve to Participate in H.C. Wainwright 24th Annual Global Investment Conference

ENGLEWOOD, CO / ACCESSWIRE / September 1, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), toda...

1 year ago - Accesswire

Viveve Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Total revenue of $1.8 million in Q2 including sale of 2,850 disposable treatment tips PURSUIT clinical trial follow-up visit completion anticipated by year end Conference call to be hosted by Company ...

1 year ago - Accesswire

Viveve to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 11, 2022

ENGLEWOOD, CO / ACCESSWIRE / July 28, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today an...

1 year ago - Accesswire

Viveve Announces Expansion of IP Portfolio with Patent Issuance in Taiwan

ENGLEWOOD, CO / ACCESSWIRE / July 12, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today an...

1 year ago - Accesswire

Viveve to Participate in H.C. Wainwright Global Investment Conference

ENGLEWOOD, CO / ACCESSWIRE / May 17, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health, today announced that Scott Durbin, chief executive officer, will...

2 years ago - Accesswire

Viveve CEO Scott Durbin Named Among Top 50 Healthcare Technology Leaders of 2022 by Healthcare Technology Report

Durbin recognized for second consecutive year for leading development of Viveve's innovative technology for treatment of stress urinary incontinence in women ENGLEWOOD, CO / ACCESSWIRE / May 17, 2022 ...

2 years ago - Accesswire

Viveve Reports First Quarter 2022 Financial Results and Provides Corporate Update

Total revenue of $1.6 million in Q1 including sale of 2,750 consumable treatment tips PURSUIT trial top-line results anticipated at end of 2022 Conference call to be hosted by Company at 5:00 PM ET to...

2 years ago - Accesswire

Viveve to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 12, 2022

ENGLEWOOD, CO / ACCESSWIRE / April 28, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its first quarter...

2 years ago - Accesswire

Viveve Reports Full Year 2021 Financial Results and Provides Corporate Update

Reported total revenue for year end 2021 of $6.4 million representing 17% year-over-year growth Enrollment completed in U.S. pivotal PURSUIT trial for stress urinary incontinence and 12-month post tre...

2 years ago - Accesswire

Viveve to Report Full Year 2021 Financial Results and Provide Corporate Update on March 17, 2022

ENGLEWOOD, CO / ACCESSWIRE / March 3, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its full year 2021...

2 years ago - Accesswire

Viveve to Participate in H.C. Wainwright BIOCONNECT Conference

ENGLEWOOD, CO / ACCESSWIRE / January 4, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health, today announced that Scott Durbin, chief executive officer, w...

2 years ago - Accesswire

Viveve Announces Completion of Full Enrollment in Pivotal U.S. PURSUIT Trial for Stress Urinary Incontinence

Major milestone achieved in Company's advance toward a new U.S. SUI indication ENGLEWOOD, CO / ACCESSWIRE / December 14, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused...

2 years ago - Accesswire

Viveve Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Total revenue of $1.6M reported for Q3 Pivotal SUI PURSUIT trial enrollment nears completion - randomizations on-track for completion in Q4 ENGLEWOOD, CO / ACCESSWIRE / November 11, 2021 / Viveve Medi...

2 years ago - Accesswire

Viveve to Host Conference Call on November 11, 2021 to Report Third Quarter Financial Results and Provide Corporate Update

ENGLEWOOD, CO / ACCESSWIRE / November 2, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its third quart...

2 years ago - Accesswire

Viveve Announces Issuance of New Device and Methods Patent in U.S

Issuance further expands and strengthens Company's intellectual property portfolio ENGLEWOOD, CO / ACCESSWIRE / October 28, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focu...

2 years ago - Accesswire

Viveve Announces Issuance of New Method Patent for Stress Urinary Incontinence in Australia

Patent strengthens and expands Viveve's intellectual property portfolio for the treatment of stress urinary incontinence ENGLEWOOD, CO / ACCESSWIRE / September 23, 2021 / Viveve Medical, Inc. (NASDAQ:...

2 years ago - Accesswire

Viveve to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

ENGLEWOOD, CO / ACCESSWIRE / September 7, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive...

2 years ago - Accesswire